Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 2300 participants.

Also called NCT07852637

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07852637
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07852637. Randomized; single masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
Acronym
NEXT-CAT
Condition
Venous Thromboembolism
Condition
Active Cancer
Intervention (Drug)
edoxaban
Intervention (Drug)
Apixaban
Lead sponsor
Samsung Medical Center (class: other)
Collaborator
Seoul National University Hospital (class: other)
Collaborator
National Cancer Center, Korea (class: other government)
Collaborator
Seoul St. Mary's Hospital (class: other)
Collaborator
Dong-A University Hospital (class: other)
Collaborator
Chonnam National University Hospital (class: other)
Collaborator
Korea University Anam Hospital (class: other)
Collaborator
Inje University Ilsan Paik Hospital (class: other)
Collaborator
Konkuk University Hospital (class: other)
Collaborator
Kangbuk Samsung Hospital, Sungkyunkwan University (class: other)
Collaborator
Chung-Ang University Gwangmyeong Hospital (class: other)
Collaborator
Chonbuk National University Hospital (class: other)

Record details

Record id
cardio:ct-nct07852637
Content hash
4ef8865500e8ee38c727d1a3df9c1820db5cdf909b27a4b850f6c5b3aea8b917